Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 83 of 157 for:    Idiopathic Dilated Cardiomyopathy

Regulation of Immunological Cytokines by Qiliqiangxin Capsule in Dilated Cardiomyopathy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02283450
Recruitment Status : Completed
First Posted : November 5, 2014
Last Update Posted : November 5, 2014
Sponsor:
Information provided by (Responsible Party):
Wei Liu, Harbin Medical University

Brief Summary:

Purpose :Research into the impact of Qiliqiangxin capsule on IFN-γ,IL-4,NT-proBNP in dilated cardiomyopathy patients with heart failure.

Methods :Data were collected from the patients with idiopathic dilated cardiomyopathy ( cardiac function NYHA Ⅱ-Ⅳ) in the first affiliated hospital of Harbin Medical University from May 2012 to April 2014. These 30 cases were treated under the recommendations of normal diagnosis and treatment in cardiomyopathy. This experiment was randomized double-blinded,the experimental interferences were avoided and patients were divided into the experimental group and the placebo group. The patients in experimental group received the relevant tests and inspections before the beginning of experiment,signed the informed consent. Then the investigators get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day,four tablets at a time. Afrer a month,the investigators evaluated the symptoms,the function of heart,blood pressure,heart rate and keep blood specimens. Three and six month later,electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done. The placebo group was followed up in the same way.


Condition or disease Intervention/treatment
Congestive Heart Failure Drug: Qiliqiangxin Capsule

Layout table for study information
Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Regulation of Immunological Cytokines by Qiliqiangxin Capsule in Dilated Cardiomyopathy patients--a Randomized Double Blind Clinical Trial
Study Start Date : May 2012
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014


Group/Cohort Intervention/treatment
the experimental group
The patients in experimental group received the relevant tests and inspections before the beginning of experiment,signed the informed consent. Then we get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day,four tablets at a time. Afrer a month,we evaluated the symptoms,the function of heart,blood pressure,heart rate and keep blood specimens. Three and six month later,electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done.
Drug: Qiliqiangxin Capsule
the placebo group
The placebo group was followed up in the same way.
Drug: Qiliqiangxin Capsule



Primary Outcome Measures :
  1. cytokine level at 3 months [ Time Frame: 3 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
congestive heart failure.
Criteria

Inclusion Criteria:

  • Congetive heart failure

Exclusion Criteria:

  • Valvular heart diseases

Layout table for additonal information
Responsible Party: Wei Liu, Prof., Harbin Medical University
ClinicalTrials.gov Identifier: NCT02283450     History of Changes
Other Study ID Numbers: 2013
First Posted: November 5, 2014    Key Record Dates
Last Update Posted: November 5, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Cardiomyopathies
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases
Cardiomegaly